, little is known about the role of SRF in tumor development. Previously, it has been reported that overexpression of SRF in Ras-transformed Rat2 fibroblast cells generates non-transformed revertants that have anchorage-dependent growth as well as reduced tumorigenecity in nude mice (Kim et al, 1994) , suggesting that the loss of SRF function might be necessary for the transformation by oncogenic Ras. Targeted deletion of the SRF gene in mice has shown that lack of SRF expression does not prevent cell proliferation and Srf -/-embryos grow and develop normally up to E6.5 (Arsenian et al, 1998) . Furthermore, Srf -/-embryonic stem (ES) cells continue to proliferate normally even with substantially reduced c-fos and Egr-1 expression, demonstrating that SRF and its responsive genes such as c-fos and Egr-1 are not required for ES cell cycle progression (Schratt et al, 2001) . Based on 2 these findings, although SRF contributes to mitogen-stimulated transcriptional induction of many immediate-early genes, one could speculate that lack of SRF expression does not impair the cell proliferation of transformed cells.
Earlier studies have demonstrated that SRF-mediated SRE-dependent transcription is a target for many different growth factors and is clearly involved in the activation of growth-factor-responsive genes (Treisman, 1994; Treisman, 1995; Whitmarsh et al, 1995) . In deed, c-Fos has oncogenic activity required for malignant progression of skin tumors (Saez et al, 1995) and is frequently overexpressed in tumor cells (MildeLangosch, 2005) . However, contrasting results also have been reported demonstrating a lack of Egr-1 or c-fos expression in chronically transformed cells by oncogenic Ras; (i) Serum inducibility of immediate early genes including Egr-1 and c-fos are suppressed at the transcriptional level in rat 3Y1 fibroblast cells stably transformed by v-Ras (Yu et al, 1993) . (ii) In the case of c-fos, PDGF or serum inducibility is markedly attenuated in v-Ras-transformed Balb/c-3T3 fibroblasts (Zullo and Faller, 1988) , in RasT24-transformed Rat1 fibroblasts (Ose-Frimpong et al, 1994) , in Ras-trasnformed rat tracheal epithelial (RTL) cells (Hubbard et al, 1996) or in H-Ras-transformed NIH3T3 cells (Mechta et al, 1997; Kessler et al, 1999) . Thus, elevation of SRE-mediated gene expression is not a general property of cells chronically transformed by oncogenic Ras.
Furthermore, it has been demonstrated that the conditional expression of c-Fos represses oncogenic Ras-driven anchorage-independent growth in vitro and suppresses tumor formation in vivo (Mikula et al, 2003) . Based on these findings, it could be speculated that SRF might function as a tumor suppressor, at least in rodent cell lines.
Alternatively, Ras-transformed cells may have reduced requirements for Egr-1 and cFos during progression of tumor development. Figure S3A) . To investigate whether this attenuation of PTEN level is associated with the reduction of Egr-1 expression, we examined the effect of small interfering RNA (siRNA) targeted to a specific sequence of Egr-1 on the alteration of PTEN protein level. When NIH3T3 cells were transfected with pSilencer/siEgr1 plasmids, both basal and PDGF-induced PTEN expression, but not GAPDH, was partially blocked (Supplemental Figure 3B) . Although it has been known that Egr-1 has distinct effects depending on whether it is activated by stress or by growth factors (Yu et al, 2004) , our result suggest that the PTEN gene could be controlled by Egr-1 in response to growth factor stimulation as well as cellular stress signals. This notion is supported by the previous report that insulin-like growth factor-II (IGF-II), a potent mitogen that promotes cell proliferation and inhibit apoptosis in breast cancer cells, increases PTEN expression via Egr-1 in the mammary gland (Moorehead et al, 2003) . Based on these findings, we suggest that the reduction of Egr-1 expression could reflect the attenuation of PTEN protein level by oncogenic Ras. Nonetheless, it appears unlikely that the attenuation of basal level of PTEN protein in oncogenic Rasexpressed cells ( Figure 8B , fourth panel) is due to the reduction of Egr-1 expression, because there was no detectable basal expression of Egr-1 in non-transformed cells.
Thus, we cannot exclude the possibility that PTEN protein level is controlled by a more complex mechanism, independently of transcriptional regulation.
Supplementary materials and methods

Plasmids, cells and stable transfection
NIH3T3 fibroblasts were cultured in Dulbecco's modified Eagle's medium (Life Technologies) that contained 10% fetal bovine serum (FBS; Hyclone). The hyperactive 5 H-Ras mutant (H-RasG12R) was generated by replacement of Gly 12 with Arg using the GeneTailer site-directed mutagenesis system (Invitrogen). The mutant was subcloned into the BamHI site of the tetracycline-inducible vector pTRE-IRES-EGFP.
To obtain tetracycline-inducible cell lines that express hyperactive H-RasG12R, pTRE-H-Ras-IRES-EGFP and pEFpuro-tet-on (generous gift of Dr. H.J. Zhu) were transfected into NIH3T3 cells using FuGENE 6 (Roche Applied Science), and the cells were selected for resistance to puromycin (20 _g/ml) for 14 days. Expression of H-RasG12R after addition of doxycycline (2 _g/ml) was verified by Western blot analysis using the anti-H-Ras antibody (F235 clone; Santa Cruz Biotechnology). In order to generate a stable cell line that expresses the H-RasV12 or H-RasV12C40 mutant, the pSG5/RasV12 or pSG5/RasV12C40 plasmid, respectively, was transfected with the pTK-Hyg selection vector (Clontech) into NIH3T3 cells using the LipofectAMINE Plus reagent (Invitrogen), as recommended by the manufacturer. The transfected cells were selected with 50 _g/ml hygromycin (Clontech) for 20-30 days. To generate a stable transfectant that expresses human PTEN, the pcDNA3.1/PTEN plasmid was transfected into U-87MG glioma cells and selected with 100 _g/ml G418 sulfate. All of the transfectants were screened by Western blot analysis using the anti-H-Ras (F235 clone; Santa Cruz Biotechnology) or anti-PTEN (Cell Signaling) antibody. Control cells were transfected with empty vector alone.
Oligonucleotide sequences for EMSA analysis
Double-stranded oligonucleotides were directed against the SRE sequence in the Egr-1 promoter: 5'-ACAGACCTTATTTGGGCAGCGCCTTATATGGAGTGGCCCAA-3' (underlined nucleotides indicate SRE2 and SRE3 motifs, respectively). The following 6 conserved SRE oligonucleotide was obtained from Santa Cruz Biotechnology: 5'-TTGGATGTCCATATTAGGACAACT-3' (conserved SRE sequence underlined).
Preparation of recombinant adenovirus expressing Egr-1
For PTEN expression, mid-log-phase cultured NIH3T3tet-on/H-RasG12R cells were infected with recombinant virus at a multiplicity of infection (m.o.i) of 20 for 1 h. After removal of the virus, the cells were cultured in the absence or presence of doxycycline (2 _g/ml) for 24 h. Uninfected or infected cells were serum-starved with 0.5% serum for an additional 24 h in the absence or presence of doxycycline, and then treated with PDGF (50 ng/ml) for 1 h.
Preparation and transfection of Egr-1 siRNA
To interfere with the expression of Egr-1 mRNA, one set of 19-mer oligonucleotides 
